Bristol-Myers Squibb Co (BMY) Position Trimmed by Guyasuta Investment Advisors Inc.

Guyasuta Investment Advisors Inc. lowered its stake in Bristol-Myers Squibb Co (NYSE:BMY) by 11.8% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 30,110 shares of the biopharmaceutical company’s stock after selling 4,020 shares during the period. Guyasuta Investment Advisors Inc.’s holdings in Bristol-Myers Squibb were worth $1,869,000 at the end of the most recent reporting period.

A number of other large investors also recently added to or reduced their stakes in BMY. CSat Investment Advisory L.P. bought a new stake in Bristol-Myers Squibb in the second quarter valued at $113,000. Cypress Capital Management LLC WY boosted its holdings in shares of Bristol-Myers Squibb by 154.7% during the 3rd quarter. Cypress Capital Management LLC WY now owns 1,910 shares of the biopharmaceutical company’s stock valued at $119,000 after buying an additional 1,160 shares in the last quarter. Landaas & Co. WI ADV bought a new stake in shares of Bristol-Myers Squibb during the 2nd quarter valued at $131,000. Selective Wealth Management bought a new stake in shares of Bristol-Myers Squibb during the 3rd quarter valued at $184,000. Finally, LFA Lugano Financial Advisors SA boosted its holdings in shares of Bristol-Myers Squibb by 85.8% during the 3rd quarter. LFA Lugano Financial Advisors SA now owns 3,207 shares of the biopharmaceutical company’s stock valued at $199,000 after buying an additional 1,481 shares in the last quarter. Institutional investors and hedge funds own 72.60% of the company’s stock.

BMY opened at $54.07 on Friday. The company has a quick ratio of 1.40, a current ratio of 1.53 and a debt-to-equity ratio of 0.41. The stock has a market capitalization of $88.25 billion, a PE ratio of 17.96, a P/E/G ratio of 1.51 and a beta of 1.08. Bristol-Myers Squibb Co has a 1 year low of $46.94 and a 1 year high of $70.05.

Bristol-Myers Squibb (NYSE:BMY) last posted its quarterly earnings results on Thursday, October 25th. The biopharmaceutical company reported $1.09 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.91 by $0.18. The firm had revenue of $5.69 billion during the quarter, compared to analyst estimates of $5.72 billion. Bristol-Myers Squibb had a return on equity of 47.89% and a net margin of 6.50%. Sell-side analysts forecast that Bristol-Myers Squibb Co will post 3.88 earnings per share for the current fiscal year.

The business also recently declared a quarterly dividend, which was paid on Thursday, November 1st. Stockholders of record on Friday, October 5th were given a $0.40 dividend. This represents a $1.60 annualized dividend and a dividend yield of 2.96%. The ex-dividend date was Thursday, October 4th. Bristol-Myers Squibb’s dividend payout ratio is presently 53.16%.

BMY has been the topic of a number of research reports. Barclays boosted their target price on shares of Bristol-Myers Squibb from $55.00 to $58.00 and gave the company an “equal weight” rating in a report on Friday, October 12th. Morgan Stanley dropped their target price on shares of Bristol-Myers Squibb from $63.00 to $59.00 and set a “hold” rating on the stock in a report on Tuesday, November 6th. Credit Suisse Group set a $61.00 target price on shares of Bristol-Myers Squibb and gave the company a “hold” rating in a report on Sunday, October 14th. Zacks Investment Research upgraded shares of Bristol-Myers Squibb from a “hold” rating to a “buy” rating and set a $70.00 target price on the stock in a report on Friday, October 5th. Finally, ValuEngine cut shares of Bristol-Myers Squibb from a “hold” rating to a “sell” rating in a report on Friday, October 19th. Three investment analysts have rated the stock with a sell rating, twelve have given a hold rating and seven have assigned a buy rating to the stock. Bristol-Myers Squibb currently has an average rating of “Hold” and an average price target of $61.84.

COPYRIGHT VIOLATION WARNING: This report was originally published by WKRB News and is the property of of WKRB News. If you are viewing this report on another site, it was copied illegally and reposted in violation of United States and international trademark & copyright law. The original version of this report can be viewed at https://www.wkrb13.com/2018/11/18/bristol-myers-squibb-co-bmy-position-trimmed-by-guyasuta-investment-advisors-inc.html.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide. The company offers drugs in various therapeutic classes, such as oncology; cardiovascular; immunoscience; and virology, including human immunodeficiency virus (HIV) infection.

Further Reading: Candlestick

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply